Research – TherapeuticsMD Inc. (TXMD) – Not Unexpected: 2020 Guidance is Suspended

Monday, March 30, 2020

TherapeuticsMD Inc. (TXMD)

Not Unexpected: 2020 Guidance is Suspended

(current) TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD’ and BocaGreenMD’ brands. The company is currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. It is also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Business update. Today, TherapeuticsMD announced a business update driven by the impact of COVID-19 pandemic. We think the implemented model is coherent in these difficult and uncertain times for an early stage commercial company like TherapeuticsMD.

    Reduced cost and spending. The Company implemented measures to cut or defer more than $30M in annual spending including $10 million deferral in Q2 marketing spend for Annovera and Imvexxy and $20 million cut in other…



    Click here to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Leave a Reply